Epstein Secrets

P, OM* • Growth factors, ctt(Npese Lumen Intim° [D.L-S P,FIT CAPITAL LLC EFTA_R1_01138815 EFTA02295541 Mechanism of Neointimal Thickening Medial SMC proliferation Lumen .Er-iclothelial cells Growth factors, ctfdlitits O° OO DACART CAPITAL Lac Intim° Adventitin EFTA_R1_01138816 EFTA02295542

regulatory and medical affairs activities associated with Cell Genesys' product portfolio. Prior to Cell Genesys, he was Chief Executive Officer of Biolitec Pharma Ltd., a U.K.-based biotechnology company, and also previously held senior executive positions with Quantanova and Scotia Holdings, plc. Prior to that, D

IMIP Lumen Intima Adventitia Fibroblasts, fat cells, interstitial matrix DACART CAPITAL LLC7 EFTA00506120 Mechanism of Neointimal Thickening Medial SMC proliferation () 0 0 0 0 0 0 0 Endothelial cells Growth factors, cit6b%-- oc) 00 Lumen Intima Fibroblasts, fat cells, interstitial IMP

regulatory and medical affairs activities associated with Cell Genesys' product portfolio. Prior to Cell Genesys, he was Chief Executive Officer of Biolitec Pharma Ltd., a U.K.-based biotechnology company, and also previously held senior executive positions with Quantanova and Scotia Holdings, plc. Prior to that, D

110 411•1. 411Mir Fibroblasts, fat cells, interstitial matrix Adventitia DACART CAPITAL LLC7 EFTA00506173 Mechanism of Neointimal Thickening Medial SMC proliferation Adventitia Fibroblasts, fat cells, intersti '- ' DACART CAP' JAL LLC: EFTA00506174 SMC migration and neointimal lesion developmen

regulatory and medical affairs activities associated with Cell Genesys' product portfolio. Prior to Cell Genesys, he was Chief Executive Officer of Biolitec Pharma Ltd., a U.K.-based biotechnology company, and also previously held senior executive positions with Quantanova and Scotia Holdings, plc. Prior to that, D